Lazard Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Lazard Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-77,200	Closed	-$885K	–	2518
2023 Q3	$885K	Buy	+77,200	New	+$1.48M	﹤0.01%	1007
2023 Q2	–	Sell	-86,155	Closed	-$2.77M	–	2586
2023 Q1	$2.77M	Buy	+86,155	New	+$2.69M	﹤0.01%	852
2022 Q3	–	Sell	-11,099	Closed	-$153K	–	2594
2022 Q2	$153K	Sell	11,099 -5,484	-33%	-$84.4K	﹤0.01%	1358
2022 Q1	$323K	Sell	16,583 -8,465	-34%	-$128K	﹤0.01%	1179
2021 Q4	$408K	Buy	+25,048	New	+$418K	﹤0.01%	1140
2021 Q3	–	Sell	-592	Closed	-$17K	–	2323
2021 Q2	$17K	Sell	592 -10,864	-95%	-$313K	﹤0.01%	1870
2021 Q1	$320K	Sell	11,456 -4,662	-29%	-$129K	﹤0.01%	1042
2020 Q4	$456K	Buy	+16,118	New	+$417K	﹤0.01%	992

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's RVNC Position: Q4 2023 in Review

Lazard Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 77,200 shares — an estimated $885K sold.

Lazard Asset Management first reported a position in RVNC in Q4 2020 and held it in 8 quarters. The position peaked at $2.77M in Q1 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

Lazard Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
Lazard Asset Management sold 77,200 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $885K.
Lazard Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 8 quarters.
Lazard Asset Management's Revance Therapeutics, Inc. position peaked at $2.77M in Q1 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.